Delving into the Latest Updates on Escitalopram with Synapse

Overview

Basic Info

SummaryEscitalopram is a selective serotonin reuptake inhibitor (SSRI) used as an antidepressant and anxiolytic medication. It was developed in close cooperation between Lundbeck and Forest Laboratories. Escitalopram was first approved by the U.S. Food and Drug Administration (FDA) in August 2002, and the approval was granted to Forest Laboratories, which was later acquired by Allergan, now part of AbbVie. Now escitalopram is marketed under various brand names, including Lexapro, Cipralex, and Seroplex, and is available in tablet and oral solution forms. Its mechanism of action involves inhibition of the reuptake of the neurotransmitter serotonin in the brain, leading to increased levels of serotonin in the synaptic cleft and enhancement of serotonergic neurotransmission. This ultimately leads to improvement in mood and reduction in anxiety symptoms. Escitalopram was originally developed and approved for the treatment of Major Depressive Disorder (MDD). It has since been approved for the treatment of Generalized Anxiety Disorder (GAD) as well.

Drug Type

Small molecule drug

Synonyms

Escitalopram (INN), 艾斯西酞普兰, Esertia

Target

SERT

Mechanism

Serotonin reuptake inhibitors

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Depressive Disorder

Originator Organization

Aquestive Therapeutics, Inc.

Active Organization

University of Oxford

Inactive Organization

Aquestive Therapeutics, Inc.

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC20H21FN2O

InChIKeyWSEQXVZVJXJVFP-FQEVSTJZSA-N

CAS Registry128196-01-0

Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), such as escitalopram are widely used for mood and anxiety disorders. However, they have also been explored, with promising findings, for a variety of disorders outside of psychiatry. Clinical studies of SSRIs in depressed people with asthma were associated with decreased asthma exacerbations and improvement in asthma control. In this study, the number of asthma exacerbations will be assessed as the primary outcome measure, in patients using escitalopram vs. placebo.

Start Date01 Apr 2025

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

[+1]

NCT06696482 / Not yet recruitingPhase 1/2IIT

Effort and Antidepressant Study Test

The aim of this study is to investigate the behavioural effects and neural correlates of increasing serotonin levels in healthy volunteers, through a 7-day course of the SSRI escitalopram, on an effort-based decision-making task measuring self-benefiting and prosocial behaviours.

Start Date01 Jan 2025

Sponsor / Collaborator

University of Oxford

[+1]

CTRI/2024/08/072643 / Not yet recruitingPhase 2/3IIT

A Comparative Study between Escitalopram (Modern Medicine) and Jyotishmati (Ayurveda) in Depressive Disorder - Treatment Trial

Start Date22 Aug 2024

Sponsor / Collaborator-

100 Clinical Results associated with Escitalopram

Login to view more data

100 Translational Medicine associated with Escitalopram

Login to view more data

100 Patents (Medical) associated with Escitalopram

Login to view more data

3,346

Literatures (Medical) associated with Escitalopram

01 Jan 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

MALDI-TOF MS-based SNP assay used to determine the appropriate antidepression for Chinese patients

Article

Author: Huang, Shanqing ; Gan, Tongying ; Shang, Dewei ; Guo, Zhihao ; Zhang, Zi

Medicine remains the preferred primary treatment for depression, although some patients show remarkable individual variations in achieving satisfactory clinical outcomes during medication. Genetic polymorphisms cause approximately 40 % of individual differences in treatment response. Therefore, this study aimed to develop a technique to identify single nucleotide polymorphisms (SNPs) associated with the metabolism, effectiveness, and side effects of antidepressant medications in Chinese patients. Bibliometrics was used to search literature related to "depression" and "SNP" in Web of Science. The obtained SNP information was screened using the PharmGKB database. By designing and optimizing primers and conducting a compound amplification system, a method was established based on MALDI-TOF MS to detect polymorphisms associated with the antidepressant drugs, including sertraline, fluoxetine, citalopram, escitalopram, venlafaxine, fluvoxamine, paroxetine, and mirtazapine. The accuracy and sensitivity of the established method were verified by Sanger sequencing. A total of 10,043 articles were screened from the database, and 46 SNPs with a mutation frequency of >1 % in Asian populations and annotated with relevant clinical drugs were extracted from the PharmGKB database. This method was compared with the results of Sanger sequencing, and the accuracy of the detection results was 100 %. The MALDI-TOF MS-based SNP assay developed in this study can be a fast, convenient and effective way for patients to find the right medication for themselves. Moreover, we found that this SNP assay holds the promise of being a potential reference tool for assessing individualised differences in drug efficacy, not only for screening the causes of poor antidepressant efficacy in patients after taking medication, but also for advising physicians to understand individualised differences in drug efficacy.

01 Jan 2025·BRAIN BEHAVIOR AND IMMUNITY

Running therapy or antidepressants as treatments for immunometabolic depression in patients with depressive and anxiety disorders: A secondary analysis of the MOTAR study

Article

Author: Penninx, Brenda W J H ; Vreijling, Sarah R ; Jansen, Rick ; Blujdea, Elena R ; Beekman, Aartjan T F ; Verhoeven, Josine E ; Teunissen, Charlotte E ; Lamers, Femke

BACKGROUND:

Exercise promotes immunometabolic health and is increasingly recognized as an effective depression treatment. Exercise may be beneficial for patients with immunometabolic depression (IMD), who experience inflammatory and metabolic dysregulations and may respond less to antidepressants. This secondary analysis of the MOTAR study compared the effects of running therapy and antidepressants on IMD features among patients with depression and/or anxiety disorder. We additionally assessed whether baseline IMD moderated intervention effects on depression.

METHODS:

Participants received 16 weeks of group-based running therapy (N = 96) or escitalopram/sertraline (N = 45) in a partially randomized patient preference design. IMD features included atypical, energy-related symptom (AES) severity, inflammation index (CRP, IFN-γ, IL-6, TNF-α), metabolic syndrome index, three metabolite principle components (PC) (derived from 73 metabolites) and a composite IMD index.

RESULTS:

Interventions differed in changes in the metabolic syndrome index (d = 0.59, p = 0.026) and IMD index (d = 0.85, p < 0.001). While running therapy decreased both outcomes, the antidepressant group showed an increased IMD index. Although groups did not differ statistically significant in changes in AES severity, inflammation index, and metabolite PC1, results indicated a consistent trend towards greater improvement with running therapy across these outcomes as well (d = 0.38 to 0.52). Baseline IMD did not moderate intervention effects on depression outcomes.

CONCLUSIONS:

This study suggests that exercise more effectively targets the IMD dimension than antidepressants. Patients with IMD did not benefit more from running therapy than antidepressants in terms of reductions in depression. Exercise should be considered an alternative or complementary treatment to particularly reduce IMD features in depressed patients.

TRIAL REGISTRATION:

Trialregister.nl Number of identification: NTR3460.

01 Jan 2025·JOURNAL OF AFFECTIVE DISORDERS

Intermittent escitalopram treatment and reactive aggression in women with premenstrual irritability and anger: A crossover study

Article

Author: Näslund, Jakob ; Eriksson, Elias ; Winblad, Stefan ; Ask, Karl ; Luke, Timothy J ; Gröndal, Maria ; Englund, Christin

BACKGROUND:

Selective serotonin reuptake inhibitors (SSRI) are the primary treatment for premenstrual mood symptoms and particularly effective in reducing reactive aggression in the forms of irritability and anger. The present study examined whether behavioral responses in laboratory measures of reactive aggression are influenced by medication with the SSRI escitalopram in women reporting high levels of premenstrual irritability/anger.

METHODS:

Participants (N = 34) rated the cardinal mood symptoms of premenstrual dysphoric disorder over three menstrual cycles. During the second and third cycles, participants received escitalopram (20 mg) or placebo in a single-blind, cross-over design. In the luteal phase of the intervention cycles, participants completed two aggression tasks: The Anger-Infused Ultimatum Game (AI-UG) and the Point Subtraction Aggression Paradigm (PSAP). Additionally, they rated expression and control of anger using the State-Trait Anger Expression Inventory-2 (STAXI-2) once in the luteal phase and once in the follicular phase.

RESULTS:

While irritability/anger was reduced in the treatment (vs. placebo) cycle, no effect of escitalopram was detected in the PSAP. Escitalopram decreased reactive aggressive behavior in the AI-UG but only for a subset of participants who experienced a sharp premenstrual rise in outwardly expressed anger and/or did not experience a premenstrual rise in inwardly expressed anger.

LIMITATIONS:

The participants' symptoms were based on the severity of only premenstrual irritability/anger, limiting the generalizability to the broader group of PMDD patients.

CONCLUSION:

The results suggest that the behavioral consequences of severe premenstrual irritability/anger are not easily captured by traditional measures of reactive aggression and underline the importance of considering individual differences in symptom expression.

1

News (Medical) associated with Escitalopram

01 Jul 2024

·www.drugs.com

Small Differences in Weight Change With First-Line Antidepressants

MONDAY, July 1, 2024 -- For eight first-line antidepressants, small differences are seen in mean weight change, with the least weight gain with bupropion, according to a study published online July 2 in the Annals of Internal Medicine . Joshua Petimar, Sc.D., from Harvard Medical School and Harvard Pilgrim Health Care Institute in Boston, and colleagues conducted an observational cohort study over 24 months to compare weight change across common first-line antidepressant treatments using electronic health record data for 183,118 patients. Initiation of treatment with sertraline, citalopram, escitalopram, fluoxetine, paroxetine, bupropion, duloxetine, or venlafaxine was ascertained using prescription data. The researchers found that the estimated six-month weight gain was higher for escitalopram, paroxetine, duloxetine, venlafaxine, and citalopram than sertraline (differences, 0.41, 0.37, 0.34, 0.17, and 0.12 kg, respectively), was similar for fluoxetine (difference, −0.07 kg), and was lower for bupropion (difference, −0.22 kg). A 10 to 15 percent higher risk for gaining at least 5 percent of baseline weight was seen for escitalopram, paroxetine, and duloxetine, while a 15 percent reduced risk was seen for bupropion. Associations were stronger, with wider confidence intervals, when the effects of initiation and adherence were estimated. There was variation seen in six-month adherence, from 28 to 42 percent for duloxetine and bupropion, respectively. "Clinicians and patients could consider these differences when making decisions about specific antidepressants, especially given the complex relationships of obesity and depression with health, quality of life, and stigma," the authors write.

Clinical Result

100 Deals associated with Escitalopram

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D07913	Escitalopram	N06AB10	DB01175

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder	Preclinical	-	Aquestive Therapeutics, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03429075 (Psilodep-RCT, CTgov)	Phase 2	Depressive Disorder, Major	59	Psilocybin + Placebo (Psilocybin)	pbmyodqodb(jjciphzsda) = qsfjbxysgd flryjkbcyh (srwwvtuzid, dqtkxipfxb - kvkntkiqzh) View more	-	24 Oct 2024
				Psilocybin + Escitalopram (Escitalopram)	pbmyodqodb(jjciphzsda) = scbirvgzef flryjkbcyh (srwwvtuzid, bmfatgbgwv - rzckzcvcgy) View more
NCT03429075 (Literature) Manual	Phase 2	Major depressive disorder, moderate (MDD)	59	Psilocybin combined with psychological support	hqavpregme(muhxorszsi): Difference = 1.51 (95% CI, -1.35 to 4.38), P-Value = 0.311 View more	Positive	21 Sep 2024
				Escitalopram combined with psychological support
NCT01479829 (CTgov)	Phase 4	Depressive Disorder \| Inflammation	100	Escitalopram+Celecoxib (Intervention Cohort)	qbintkozmj(lebyoofepk): Chi-square value = 5.3466, P-Value = 0.02 View more	-	09 Apr 2024
				Placebo+Escitalopram (Control Cohort)
NCT03388164 (CTgov)	Phase 2	Depressive Disorder	23	RT2CK17+Escitalopram (Escitalopram + RT2CK17)	tzutrrsoxy(uixniouhek) = eqxlcjrlya igaxjuphaw (emfdlgqjhf, wciruegwjp - mumpdhfucp) View more	-	16 Sep 2021
				Escitalopram + Placebo (Escitalopram + Placebo)	tzutrrsoxy(uixniouhek) = tgzlrgjcwe igaxjuphaw (emfdlgqjhf, qqrzbcbgbr - zeewfxkdzz) View more
AAIC2016	Not Applicable	-	-	Escitalopram 20 mg/day	kwlqplfxnv(lrzlwewsbk) = zjuagmriis zxsbhhfebm (bpbiaqwgnq )	-	01 Jul 2016
				Placebo	kwlqplfxnv(lrzlwewsbk) = qpjgyrgpic zxsbhhfebm (bpbiaqwgnq )
ISC2016	Not Applicable	Cognition \| Nervous System Diseases \| Mood Disorders	405	Escitalopram	njmxavthtp(nhplcmlsgs) = tldrtvsctr fwtcomkffv (zsmpzpdydw )	Negative	01 Feb 2016
				Placebo	njmxavthtp(nhplcmlsgs) = vgbnlvtaku fwtcomkffv (zsmpzpdydw )
NCT00746239 (CTgov)	Not Applicable	Sleep Initiation and Maintenance Disorders \| Anxiety Disorders \| Panic Disorder	11	Placebo+Escitalopram+Ramelteon	mhvkmbukpq(owiwzdblqw) = mkoaokmxrj vvqvyvlrqc (kqsyokasps, vvmihcktdf - bjlldbjggg) View more	-	15 Oct 2015
NCT01876823 (CTgov)	Phase 2/3	Alzheimer Disease \| Depressive Disorder, Major \| Mild cognitive disorder	60	es-citalopram+memantine	ogemrdzhfn(flfwbjilgr) = nuqbasriiw eywhttmwbt (njfbvxttuu, adplxcttpu - tfpslelbor) View more	-	24 Oct 2014
NCT00361218 (CTgov)	Phase 3	Depressive Disorder, Major	72	escitalopram+citalopram	dmkmplnxrd(vkeylefzwc) = ocegxlvoid cyftehxzgg (gokrwtgufl, wexggxzdvz - izefjvkbgc) View more	-	26 Sep 2013
AAIC2009	Not Applicable	Impairment of Executive Functions	135	Escitalopram	ewkmkzrzig(mrjhczcmga) = kphckgmeyz wegvwmxqmj (kepgvqmkuq )	-	01 Jul 2009
				Tianeptine	ewkmkzrzig(mrjhczcmga) = cclrcdgfag wegvwmxqmj (kepgvqmkuq )